Últimas noticias sobre CureVac (NASDAQ:CVAC) Bolsa

CureVac

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Large Cap

News

Health Care

General

CVAC

MRNA

NVAX

Un trabajador lechero en Nevada da positivo en gripe aviar H5N1. CDC investiga mientras la cepa se propaga en aves y ganado.

Gripe aviar en EE.UU.: trabajador lechero en Nevada da positivo

CureVac NV

Biotech

Government

Regulations

BBIO

BEYONTTRA Receives European Commission Marketing Authorization For BEYONTTRA For Treatment Of ATTR-CM

B of A Securities analyst Steve Byrne maintains Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) with a Buy and lowers the price target from $105 to $87.

Price Target

Analyst Ratings

B of A Securities Maintains Buy on Bunge Global, Lowers Price Target to $87

Barclays analyst Tim Long maintains Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) with a Equal-Weight and lowers the price target from $14 to $10.

HLIT

Barclays Maintains Equal-Weight on Harmonic, Lowers Price Target to $10

Contracts

ESEA

Euroseas Announces 2-Year Charter Contract Extension For Feeder Containership, M/V EM Hydra; For Minimum Period Of 24 Months And Maximum Period Of 26 Months At Gross Daily Rate Of $19,000

B of A Securities analyst Michael Cherny maintains Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) with a Buy and raises the price target from $21 to $25.

PGNY

B of A Securities Maintains Buy on Progyny, Raises Price Target to $25

B of A Securities analyst Salvator Tiano maintains Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) with a Underperform and lowers the price target from $54 to $48.

B of A Securities Maintains Underperform on Archer-Daniels Midland, Lowers Price Target to $48

Results demonstrate that CELZ-201 achieved an 80% overall efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels, with no serious adverse effects reported.

CELZ

Creative Medical Technology Reports One-Year Results For AlloStem Type 2 Diabetes Program

Macro Economic Events

Economics

Federal Reserve

Fed's Hammack Says Will Evaluate Trump Economic And Trade Policies As They Come In

Barclays analyst Dan Levy maintains BorgWarner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) with a Overweight and lowers the price target from $43 to $42.

Barclays Maintains Overweight on BorgWarner, Lowers Price Target to $42

B of A Securities analyst Steve Byrne maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Buy and raises the price target from $69 to $73.

CTVA

B of A Securities Maintains Buy on Corteva, Raises Price Target to $73

As of Feb. 11, 2025, two stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Zillow Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>)</h3>
<ul>
<li>On Feb. 5, Benchmark analyst Daniel Kurnos maintained Zillow with a Buy and raised the price target from $80 to $100. The company's stock gained around 25% over the past month and has a <a href="https://www.benzinga.com/quote/ZG">52-week high of $85.89</a>.</li>
<li>RSI Value: 75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ZG Price Action: Shares of Zillow gained 1% to close at $85.29 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Welltower Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>)</h3>
<ul>
<li>On Jan. 29, NorthStar Healthcare Income, Inc. agreed to be acquired by an affiliate of Welltower for $3.03 per share in a $900 million transaction. Nikhil Chaudhri, Co-President and Chief Investment Officer of Welltower said, &#8220;We are delighted to have reached an agreement to acquire NorthStar&#8217;s portfolio of 40 seniors housing communities, which portfolio, subject to satisfaction of closing conditions and closing under the merger agreement, Welltower anticipates will be allocated to an entity affiliated with its recently announced funds management business." The company's stock gained around 14% over the past month and <a href="https://www.benzinga.com/quote/WELL">has a 52-week high</a> of $143.84.</li>
<li>RSI Value: 70.8</li>
<li>WELL Price Action: Shares of Welltower gained 0.4% to close at $143.11 on Monday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

WELL

Top 2 Real Estate Stocks You May Want To Dump In February

WIIM

WESCO shares are trading lower following a Q4 EPS miss.

Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) reported better-than-expected first-quarter <a href="https://www.benzinga.com/quote/ROK/earnings">earnings on Monday</a>.
Sales fell 8.4% year over year and slid 7.6% organically to $1.881 billion, in line with the consensus of $1.881 billion. Total ARR grew 11%. Adjusted EPS was $1.83 (-10% YoY), above the analyst consensus of $1.59.
"From a demand perspective, we are encouraged by better-than-expected order performance in the quarter with sequential growth across all regions and business segments. While there is still some macroeconomic and policy uncertainty weighing on customers&#8217; capex plans, Rockwell won multi-million dollar strategic orders across key industries, especially in the U.S., our home market," commented Blake Moret, Chairman and CEO.
Rockwell Automation shares gained 12.7% to close at $302.34 on Monday.
These analysts made changes to their price targets on Rockwell Automation following earnings announcement.
<ul>
<li>Citigroup analyst Andrew Kaplowitz maintained Rockwell Automation with a Buy and raised the price target from $345 to $350.</li>
<li>Wells Fargo analyst Joseph O&#8217;Dea maintained the stock with an Overweight and raised the price target from $315 to $337.</li>
<li>Baird analyst Richard Eastman maintained the stock with an Outperform and raised the price target from $305 to $315.</li>
<li>Oppenheimer analyst Noah Kaye maintained Rockwell Automation with an Outperform and raised the price target from $300 to $320.</li>
</ul>
Considering buying ROK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11091647/image-2-26-1024x589.png" alt="" class="wp-image-776671" style="width:506px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11091647/image-2-26-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11091647/image-2-26-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11091647/image-2-26-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11091647/image-2-26.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43592071/top-3-tech-stocks-that-may-jump-this-month">Top 3 Tech Stocks That May Jump This Mon</a>th</li>
</ul>

Earnings

Rockwell Automation Analysts Increase Their Forecasts After Upbeat Earnings

<a href="https://shareholder.ford.com/Investors/events/event-details/2025/Farley-House-to-Participate-in-the-Wolfe-Research-Auto-Auto-Tech-and-Semiconductor-Conference/default.aspx" title="https://shareholder.ford.com/Investors/events/event-details/2025/Farley-House-to-Participate-in-the-Wolfe-Research-Auto-Auto-Tech-and-Semiconductor-Conference/default.aspx">https://shareholder.ford.com/Investors/events/event-details/2025/Farley-House-to-Participate-in-the-Wolfe-Research-Auto-Auto-Tech-and-Semiconductor-Conference/default.aspx</a>

Ford CFO Says Considering Where To Build Inventory To Prepare For Mexico And Canada Tariffs; Ford Gets Most Of Its Aluminum And Steel From U.S, Sources

<ul>
<li>SMCI</li>
<li>TSLA</li>
<li>NVDA</li>
<li>PLTR</li>
<li>GOOGL</li>
<li>ACHR</li>
<li>GLD</li>
<li>AAPl</li>
<li>META</li>
<li>AMD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

ACHR

GOOGL

NVDA

PLTR

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of February 11, 2025 (Via Swaggy Stocks)

Barclays analyst Andrew Lazar maintains Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) with a Equal-Weight and lowers the price target from $6 to $5.

HAIN

Barclays Maintains Equal-Weight on Hain Celestial Group, Lowers Price Target to $5

Barclays analyst Lauren Lieberman maintains Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) with a Equal-Weight and lowers the price target from $33 to $30.

Barclays Maintains Equal-Weight on Edgewell Personal Care, Lowers Price Target to $30

ORMP

Oramed Announces Entered Into Definitive Agremeents To Spin Off Protein Oral Delivery Technology Into Joint Venture With Hefei Tianhui Biotech

Management

Tejon Ranch Appoints Matthew Walker As President & CEO; Succeeds Gregory S. Bielli

S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) shares are trading higher<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> in the premarket session on Tuesday.</a>
The company reported <a target="_blank" href="https://s29.q4cdn.com/690959130/files/doc_financials/2024/q4/S-P-Global-4Q-and-Full-Year-2024-Earnings-Release-Exhibits-2-11-2025.pdf" rel="noreferrer noopener">fourth-quarter</a> adjusted earnings per share of $3.77, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43619727/s-p-global-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">beating the street view of $3.48</a>. Quarterly sales of $3.592 billion (+14%) outpaced the analyst consensus estimate of $3.503 billion, driven by growth in all divisions. Revenue from subscription products increased 6%.
The company said it successfully executed its leadership transition, with Martina Cheung assuming the role of President and CEO on November 1, 2024.
&#8220;As S&amp;P Global&#8217;s new CEO, I have had hundreds of conversations with our customers and partners, who have reinforced the need for our benchmarks, data, and insights to guide their decisions in a constantly evolving market,&#8221; Cheung added.
Adjusted operating profit margin increased 260 basis points to 46.7%, primarily due to strength in the Ratings unit.
Also Read:<a target="_blank" href="https://www.benzinga.com/25/02/43621782/insurance-giant-humanas-q4-earnings-at-par-with-estimates-2025-profit-outlook-falls-below-street-view" rel="noreferrer noopener"> Insurance Giant Humana&#8217;s Q4 Earnings: 13% Revenue Growth, 2025 Profit Outlook Falls Below Street View</a>
The company exited the quarter with cash and equivalents worth $1.66 billion.
Long-term debt as of quarter end totaled $11.394 billion.
S&amp;P Global recently authorized a quarterly <a target="_blank" href="https://www.benzinga.com//node/43286805" rel="noreferrer noopener">cash dividend of $0.96</a>, marking the company&#8217;s 52nd consecutive year of dividend increases. Additionally, the Board has authorized the repurchase of shares totaling up to $4.3 billion. The company expects to launch an initial $650 million Accelerated Share Repurchase in the coming weeks.
Outlook: For the full year 2025, S&amp;P Global maintains its target of returning 85% or more of adjusted free cash flow to shareholders through dividends and share repurchases.
The company projects FY25 revenue growth of 5% &#8211; 7%, along with adjusted EPS in the range of $17.00 to $17.25. This guidance is <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">above the $16.92 estimate.</a>
S&amp;P Global expects 2025 cash provided by operating activities, less capital expenditures and distributions to noncontrolling interest holders, of ~$5.9 billion. It expects adjusted free cash flow, excluding certain items, of $6 billion.
Price Action: SPGI shares are trading higher by 5.96% to $546.00 premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43604305/what-to-expect-when-biotech-giant-gilead-reports-q4-earnings-on-tuesday" target="_blank" rel="noreferrer noopener">What To Expect When Biotech Giant Gilead Reports Q4 Earnings On Tuesday?</a></li>
</ul>
Photo via Shutterstock.

Equities

Guidance

Dividends

Buybacks

Movers

SPGI

S&P Global's Ratings Power Q4 Surge, Capital Returns Sweeten The Deal

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company's shares closed yes...

Leerink Partners Sticks to Their Hold Rating for CureVac (CVAC)

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00. Roy Bucha...

CureVac: Strong Financial Position and Promising Pipeline Justify Buy Rating

California Gov. Newsom declares State of Emergency over bird flu

Vaccine stocks gain amid uptick in flu, COVID-19, RSV

Bird flu claims first U.S. life in Louisiana

Shares of Moderna (MRNA), one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, were up nearly 10% in early trading after t...

Bird flu vaccine maker Moderna shares jump after first US death, Barron's says

Moderna, Novavax and other vaccine names extend gains amid COVID/flu concerns

Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

Bird flu reaches NYC as live poultry markets shut down

ABUS

ARCT

BNTX

CSLLY

GLAXF

ROIV

Press Releases

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza  mRNA Vaccine Program

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Events

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

CureVac to Present at the 12th International mRNA Health Conference

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

JMP Securities

Leerink Partners

B of A Securities

SVB Securities

Comments

CureVac

Noticias

Últimas noticias sobre CureVac (NASDAQ:CVAC) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL